United States Interventional Cardiology and Peripheral Vascular Devices Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The global interventional cardiology and peripheral vascular devices market reached US$ 20.11 billion in 2023, with a rise to US$ 21.58 billion in 2024, and is expected to reach US$ 41.17 billion by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/interventional-cardiology-and-peripheral-vascular-devices-market?sb

Key Development:

United States: Recent Interventional Cardiology & Peripheral Vascular Device Developments

✅ In December 2025, the U.S. Food and Drug Administration granted approval to Abbott's Volt Pulsed Field Ablation (PFA) System, a novel catheter‐based ablation technology designed to treat arrhythmias with conscious sedation and expanded catheter lab treatment options for structural heart and vascular procedures.

✅ In November 2025, Terumo Interventional Systems' OPUSWAVE® Dual Sensor Imaging System and DualView® imaging catheter received FDA 510(k) clearance, enabling combined OFDI + IVUS coronary imaging that can shorten procedure time and improve vessel assessment in percutaneous interventions.

✅ In November 2025, Stereotaxis' GenesisXTM robotic magnetic navigation system received FDA 510(k) clearance, advancing minimally invasive endovascular navigation for complex coronary and peripheral interventions.

✅ In December 2025, the FDA's Circulatory System Devices Advisory Panel scheduled a review of V‐Wave's Ventura Interatrial Shunt System PMA, a first‐of‐its‐kind permanent implant for symptomatic chronic heart failure patients, marking a key regulatory milestone toward future approval.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=interventional-cardiology-and-peripheral-vascular-devices-market

Japan: Recent Interventional Cardiology & Peripheral Vascular Device Developments

✅ In October 2025, Terumo's interventional systems division announced the U.S. FDA 510(k) clearance of its OPUSWAVE® dual imaging platform and DualView® catheter, representing a major imaging innovation co‐developed in Japan that integrates two key intravascular visualization modalities.

✅ In Late 2025, Japanese Medtronic products Aurora EV ICDTM MRI device and Epsila EV MRI leads were recognized with design awards, highlighting advanced low‐invasive structural cardiac device innovation originating in Japan, including stent systems.

✅ In Q4 2025, Japanese research initiatives in cardiovascular prototype and catheter technologies under government‐sponsored programs progressed, focusing on high‐value consumable vascular devices and novel transcatheter low‐invasive systems toward domestic innovation leadership.

✅ In Late 2025, Japanese market and development reports indicated a continued push in novel stent and catheter device advances for interventional procedures, especially in coronary occlusion and occlusion‐closure devices, driven by low‐invasive care demand.

Key Players:

=> B. Braun Interventional Systems Inc., Boston Scientific Corporation, BD, Medtronic, Teleflex Incorporated, Lepu Medical Technology (Beijing) Co., Ltd, TERUMO CORPORATION, Cook, Shenzhen MicroApproach Medical Technology Co., Ltd, and Biotronik, among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/interventional-cardiology-and-peripheral-vascular-devices-market?sb

Key Segments:

By Product Type

Interventional Catheters - ~20% share, widely used in minimally invasive cardiac procedures.
Guidewires - ~15% share, essential for navigating vascular pathways during interventions.
Stents - ~25% share, dominant segment due to high prevalence of coronary artery disease.
PTCA Balloons - ~10% share, used in balloon angioplasty procedures.
Atherectomy Devices - ~5% share, specialized use for plaque removal in arteries.
Chronic Total Occlusion Devices - ~5% share, niche application for total arterial blockages.
Synthetic Surgical Grafts - ~5% share, employed in bypass and vascular reconstruction.
Embolic Protection Devices - ~5% share, used to prevent distal embolization during interventions.
IVC Filters - ~5% share, applied for preventing pulmonary embolism.
Others - ~5% share, including emerging minimally invasive cardiovascular devices.

By Application

Congenital Heart Defect Correction - ~10% share, growing pediatric and adult corrective interventions.
Coronary Thrombectomy - ~15% share, used for removing clots in coronary arteries.
Angioplasty - ~25% share, primary application for revascularization procedures.
Valvuloplasty - ~10% share, used for repairing stenotic heart valves.
Percutaneous Valve Repair - ~15% share, expanding adoption due to minimally invasive valve procedures.
Others - ~25% share, including emerging cardiovascular interventions.

By End-User

Hospitals - ~70% share, major adopters of interventional cardiovascular devices.
Ambulatory Surgical Centers - ~20% share, increasing outpatient procedures driving adoption.
Others - ~10% share, including research facilities and specialized cardiovascular centers.

By Region

North America - 40% Share
Highly advanced healthcare infrastructure and high adoption of minimally invasive cardiac devices.

Europe - 25% Share
Strong reimbursement systems and growing demand for percutaneous interventions.

Asia Pacific - 20% Share
Rapidly growing patient pool with increasing incidence of cardiovascular diseases.

Latin America - 10% Share
Urban hospitals driving adoption, gradual expansion in emerging markets.

Middle East & Africa - 5% Share
Emerging market with adoption in private hospitals and specialty clinics.

FAQ

What is the current size of the Interventional cardiology and peripheral vascular devices Market?

A: In 2024, the Interventional cardiology and peripheral vascular devices Market was valued at US$ 21.58 billion , reflecting its strong industry presence.

Q2: How large is the Interventional cardiology and peripheral vascular devices Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Interventional cardiology and peripheral vascular devices Market will grow to around US$ 41.17 billion , demonstrating significant expansion.

Q3: What is the growth rate of the Interventional cardiology and peripheral vascular devices Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.